Wall Street Analysts See a 67.54% Upside in CRISPR Therapeutics (CRSP): Can the Stock Really Move This High?

CRISPR Therapeutics AG (CRSP) closed the last trading session at $48.92, gaining 1.5% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by Wall Street analysts are any guide. The mean price target of $81.96 indicates a 67.5% upside potential. The average comprises 24 short-term price targets ranging from a low of $30 to a high of $199, with a standard deviation of $34.57. While the lowest estimate indicates a decline of 38.7% from the current pri ...